The post Robinhood’s RVI Stock Plunges 16% After IPO Falls Short of $1B Target appeared on BitcoinEthereumNews.com. Robinhood’s RVI stock has fallen by 16% at theThe post Robinhood’s RVI Stock Plunges 16% After IPO Falls Short of $1B Target appeared on BitcoinEthereumNews.com. Robinhood’s RVI stock has fallen by 16% at the

Robinhood’s RVI Stock Plunges 16% After IPO Falls Short of $1B Target

For feedback or concerns regarding this content, please contact us at [email protected]

Robinhood’s RVI stock has fallen by 16% at the start of its trading yesterday. This came after the initiative failed to meet its $1 billion in its IPO raise plan.

Robinhood’s RVI Stock Stumbles After Weak IPO Raise

Venture Fund I of the investment firm Robinhood fell 16% in its public market debut on the New York Stock Exchange on Friday after its IPO failed to meet its IPO target. The fund, which now trades under the symbol “RVI,” provides access to prominent private companies.

Source: Yahoo Finance; RVI stock daily price chart

In an interview on CNBC’s “Squawk Box” on Friday, Vlad Tenev, the CEO of Robinhood, said the RVI stock seeks to allow access to a segment of the capital markets that has traditionally been closed to retail investors.

Investors can buy and sell shares of the closed-end fund, which is structured like an investment firm. However, this went public at a difficult time for the markets. The major U.S. stock averages are on course for a weekly decline. This comes as investors sell shares due to fears of the U.S.-Iran conflict potentially lasting longer than expected.

Robinhood’s RVI stock priced its initial public offering at $25 a share. The stock opened at $22 a share and closed on Friday at $21 a share.

RVI IPO Pulls In $668M, Missing $1B Goal

The fund listed on the stock exchange, after missing its target by more than $300 million. As CoinGape reported in February, Robinhood Markets said it plans to raise $1 billion from its initial public offering of the closed-end fund. The initial date for the start of trading was set for February 26, but the listing was delayed by a week.

Robinhood’s RVI stock also holds stakes in top private companies. This includes Databricks, Ramp, and Revolut. The crypto exchange sold 12.6 million shares, fewer than the company had initially sought from its IPO.

There is still some caution from investors regarding crypto IPOs, as the markets are still volatile in the current cycle

Source: https://coingape.com/news/stocks/robinhoods-rvi-stock-plunges-16-after-ipo-falls-short-of-1b-target/

Market Opportunity
PUBLIC Logo
PUBLIC Price(PUBLIC)
$0.01511
$0.01511$0.01511
+0.19%
USD
PUBLIC (PUBLIC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09